Tumor Treating Fields Plus SOC May Benefit OS in Metastatic NSCLC
June 7th 2023The results of the phase 3 LUNAR trial evaluating tumor treating fields plus standard-of-care therapies among patients with metastatic non–small cell lung cancer are “encouraging,” according to an expert from Winship Cancer Institute of Emory University.
Neoadjuvant Nivolumab/Chemo Improves Outcomes Vs Chemo in Resectable NSCLC
June 4th 2023Patients who receive nivolumab plus chemotherapy for non–small cell lung cancer may experience sustained improvement in time to death or distant metastasis, according to an expert from McGill University Health Center.